SIGA Technologies, Inc. Profile
Industry
Drug Manufacturers - Specialty & GenericSector
HealthcareNumber of Employees
45SIGA Technologies's Business Model
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
About SIGA Technologies
Website: https://www.siga.com
CEO (Chief Executive Officer): Dr. Diem Nguyen M.B.A., Ph.D.
IPO date: 1997-09-10
Contact
Country: US
Address: 31 East 62nd Street
City: New York
State: NY
Phone: 212 672 9100
Zip Code: 10065
Other
CIK: 0001010086
ISIN: US8269171067
CUSIP: 826917106
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
